<DOC>
	<DOCNO>NCT02944955</DOCNO>
	<brief_summary>This clinical trial determine safety , recommend dose level ( RDL ) , infection control BLEX 404 Oral Liquid combination azacitidine patient International Prognostic Scoring System ( IPSS ) intermediate-1 ( int-1 ) , intermediate-2 ( int-2 ) high-risk myelodysplastic syndrome ( MDS ) Chronic Myelomonocytic Leukemia ( CMML ) .</brief_summary>
	<brief_title>A Study BLEX 404 Oral Liquid Patients With International Prognostic Scoring System ( IPSS ) Intermediate-1 , Intermediate-2 High-Risk Myelodysplastic Syndrome ( MDS ) Chronic Myelomonocytic Leukemia ( CMML )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Age 20 old , able sign inform consent , understand comply protocol requirement instruction . Body weight 30 120 kg International Prognostic Scoring System ( IPSS ) intermediate1 ( int1 ) , intermediate2 ( int2 ) highrisk myelodysplastic syndrome ( MDS ) World Health Organization ( WHO ) Chronic Myelomonocytic Leukemia ( CMML ) patient . Not previously treat MDS CMML therapy require treatment azacitidine* first time 75 mg/m2 subcutaneously intravenously , daily 7 day ( 7 nonconsecutive day 611 522 treatment schedule acceptable drug administer MondaySaturday Monday follow week 611 schedule , drug administer MondayFriday MondayTuesday follow week 522 schedule ) per cycle . Treatment study drug , BLEX 404 Oral Liquid begin time receive first dose azacitidine study . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 03 . Adequate baseline organ function define criterion : total bilirubin ≤ 1.5x upper limit normal ( ULN ) except Gilbert 's syndrome indirect hyperbilirubinemia due hemolysis ; ALT ≤ 2.5x ULN ; AST ≤ 2.5x ULN ; creatinine clearance ≥ 60 mL/min/1.73 m2 . Women must either nonchild bear potential , woman childbearing potential men reproductive potential female partner childbearing potential must either prior vasectomy agree use effective contraception time Screening Visit FollowUp Visit . Historical allergic event cause mushroom . Previous treatment hypomethylating agent know immediate delay hypersensitivity reaction drug chemically relate azacitidine contraindicate subject ' participation . Patients active infection require treatment immunosuppressive drug screen visit . However , patient require ongoing treatment corticosteroid may recruit . Treatment investigational drug within 30 day 5 halflives ( whichever longer ) precede first dose BLEX 404 Oral Liquid . Any serious and/or unstable preexist medical condition ( include advanced malignancy disease study ) , psychiatric disorder , condition could interfere subject 's safety , obtain informed consent compliance study procedure . Any clinically significant pulmonary , cardiovascular , endocrine , neurologic , gastrointestinal genitourinary disease unrelated underlying hematologic disorder . Active uncontrolled infection follow : hepatitis B ( HBV ) , hepatitis C ( HCV ) , human immunodeficiency virus ( HIV ) infection . However , HBV HCV carrier viral load test `` detect '' `` negative '' result may recruit study . Lactating female woman positive serum urine pregnancy test screening assessment . ( For Part II Interventional Study subject ) No indication , opinion treat physician , antibiotic prophylaxis within 2 week prior study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>